36Kr Holdings learned that the coronary stent developer "Prozac" announced the completion of tens of millions of yuan of B + round financing, this round of financing led by Yuansheng Venture Capital, followed by Chende Capital. This is the second round of financing obtained by Baixin an this year after the completion of round B financing in November, raising more than 100 million yuan in the two rounds.

This round of funds will continue to be used to promote the registration and listing of phase 3 clinical trials of the company's Bio-heart bioabsorbable coronary stents and related products.

Bai Xin'an is mainly engaged in the research, development, production and sales of coronary stents, and its core product is a new generation of bioabsorbable coronary stent system Bio-heart, which is mainly used in cardiac stent surgery to restore normal blood flow at the narrowing or clogging of the coronary artery.

It is understood that Bio-heart can help to achieve revascularization, eventually return blood vessels to normal state, and can expand and contract according to changes in blood flow demand. At present, the domestic drug-eluting stent has been developed very mature, and the domestic replacement has been completed on a large scale. "compared with the recently listed absorbable drug-eluting stents, the wall thickness of Propranolol stents is only 60 to 70 per cent of their thickness," founder Wang Li stressed that Bio-heart is characterized by "thin".

Bio-heart is conducting phase III clinical trials, which are expected to be completed by 2020, followed by at least two years of clinical follow-up, which is expected to be available in 2022.

At present, Bai Xin'an has applied for a number of patents, and 14 countries have submitted applications for invention patents, of which 4 invention patents and 21 utility model patents have been granted.

At present, the number of patients with coronary heart disease in China is as high as 11 million. In 2018, there were 915000 interventional operations for coronary heart disease in China, with an average annual growth rate of 16.7%. 1.33 million stents were implanted in interventional therapy.

Cardiac interventional devices have become one of the hottest directions in the research and development of medical devices in the world, and are predicted to be one of the ten most influential medical innovations in 2019. Related interventional devices and matching high-end consumable products are also developing rapidly. Medical device giants Medtronic PLC, Abbott Laboratories, Edward Life Sciences and so on have entered this field. Among them, the localization rate of the most mature coronary stents has exceeded 75%, and import substitution has been basically completed.

For this kind of medical innovation, the national policy also gives great encouragement, the implementation level bidding and medical insurance fees are tilted to this kind of domestic products, the next decade will be the golden period of import substitution in the field of domestic medical consumables.